Initial upload of fine-tuned PatentSBERTa Specialist (eHealth)

README.md

@@ -5,38 +5,717 @@ tags:
 - feature-extraction
 - dense
 - generated_from_trainer
-- dataset_size:2633
+- dataset_size:2369
 - loss:MultipleNegativesRankingLoss
-- dataset_size:7861
+- dataset_size:6288
 base_model: AI-Growth-Lab/PatentSBERTa
 widget:
-- source_sentence: CONSORTIUM OF PROBIOTICS.
+- source_sentence: "COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN FOR USE IN\
+    \ TREATMENT OF BONE DISEAS. Title: COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN\
+    \ FOR USE IN TREATMENT OF BONE DISEAS\n\nAbstract: \n\nBusiness Description: The\
+    \ patent concerns the possible use of polydatin for the treatment of pathologies\
+    \ characterized by reduced bone mass. Polydatin is an oligostilbene that can be\
+    \ extracted in abundant quantities from the roots of the Polygonum Cuspidatum\
+    \ plant and, according to our studies about osteoblastic proliferation and differentiation,\
+    \ is able to increase osteogenic activity.\n\nTech Features: Skeletal pathologies\
+    \ are widespread in the world population, more than 200 million people are osteoporosis\
+    \ patients and have a high probability of fracture. Polydatin is a substance of\
+    \ natural origin, free of the side effects related to the use of synthetic drugs, currently\
+    \ administered for the treatment of bone loss diseases . Our experiments carried\
+    \ out in two-dimensional cultures (2D) and in cells grown on Scaffold (3D), have\
+    \ shown that polydatin is able to increase the activity of osteoblasts (ALP) and\
+    \ the deposition of Bone Matrix. The compositions comprising or consisting of\
+    \ polydatin may be administered orally (for example capsules or tablets, solutions,\
+    \ emulsions) or topically (oils, creams, ointments), or even through an appropriate\
+    \ enrichment of the active ingredient in functional foods\n\nApplications: Patients\
+    \ with traumatic-degenerative pathologies of the skeleton and oral cavity; Osteoporosis\
+    \ patients;\n\nAdvantages: Molecule of natural origin; Antioxidant activity on\
+    \ the whole organism; Possibility of topical use;"
   sentences:
-  - NANOSTRUCTURED FILTERING MEMBRANE FOR ANALYTICAL APPLICATIONS.
-  - CONSORTIUM OF PROBIOTICS.
-  - Real-time communications over Bluetooth Low Energy.
-- source_sentence: Device for the collection and analysis of a biological fluid.
+  - "Inhibitory compounds neurodegeneration and tumors. Title: Inhibitory compounds\
+    \ neurodegeneration and tumors\n\nAbstract: \n\nBusiness Description: The inhibition\
+    \ of the monoacylglycerol lipase enzyme (MAGL), naturally present in many brain\
+    \ cells and involved in physio-pathological processes, has a high therapeutic\
+    \ potential: neurodegenerative inflammation pathologies and tumors could be treated\
+    \ with new reversible inhibitory compounds, which would reduce the side effects\
+    \ of the irreversible inhibitors tested so far.\n\nTech Features: Monoacylglycerol\
+    \ lipase (MAGL) is a human enzyme of the endocannabinoid system involved in numerous\
+    \ physio-pathological processes (regulation of inflammation, anxiety, immune modulation,\
+    \ motor coordination ...), yet its overexpression/upregulation can cause neuroinflammatory\
+    \ diseases and tumors. The inhibition of MAGL for therapeutic purposes has been\
+    \ studied so far with irreversible inhibitors, which however nullify the enzyme\
+    \ activity, leading to a progressive loss of the therapeutic effect and to addiction\
+    \ phenomena. On the contrary, the new-patented compounds based on a strong non-covalent\
+    \ reversible mechanism of action avoid the side effects mentioned. Effective in\
+    \ laboratory on various tumor cell lines (e.g. colorectal, breast and ovarian\
+    \ cancer), they could also treat other MAGL-mediated pathologies (neuroinflammation/degeneration,\
+    \ pain, amyotrophic multiple/lateral sclerosis, Alzheimer's disease, Parkinson's\
+    \ disease). Link to scientific publication and information on Ca' Foscari website\n\
+    \nApplications: Innovative and less harmful pharmaceutical compositions for the\
+    \ treatment of serious neurodegenerative pathological conditions; Innovative and\
+    \ less harmful pharmaceutical compositions for cancer treatment.\n\nAdvantages:\
+    \ Temporary nature and reversibility; Drastic reduction of side effects; High\
+    \ efficacy tested on tumor cell lines; Exploitable to treat numerous neurodegenerative\
+    \ diseases; One of the few non-covalent reversible MAGL inhibitors with high efficacy."
+  - 'New computational method for the prognosis of amyotrophic lateral sclerosis.
+    Title: New computational method for the prognosis of amyotrophic lateral sclerosis
+
+
+    Abstract: A method is described for determining a disease progression and survival
+    prognosis, at a succession of prediction times, for patients suffering from amyotrophic
+    lateral sclerosis (ALS). The method comprises a step of defining a set of variables
+    associated with the onset and progression of amyotrophic lateral sclerosis, comprising
+    a first group of variables associated with the onset of amyotrophic lateral sclerosis
+    (comprising at least the variables “patient sex”, “disease onset age”, “disease
+    onset site”), a second group of dynamic time variables (comprising at least the
+    variable “time elapsed since disease onset”), a third group of dynamic functional
+    variables (comprising at least one of the variables breathing, swallowing, communicating,
+    walking/self-care or at least one variable of a functional progression and/or
+    severity scale of amyotrophic lateral sclerosis), and further at least one variable
+    associated with survival. The method further provides for encoding by means of
+    a Dynamic Bayesian Network, using at least one trained algorithm, a plurality
+    of probabilistic conditional dependence relationships, in which each relationship
+    is a probabilistic conditional dependence relationship between two of the aforesaid
+    variables. The aforesaid prediction times are defined so that each prediction
+    time belongs to a respective time interval in which the conditional dependence
+    relationships between the variables are stationary. The method further involves
+    describing the Dynamic Bayesian Network, using at least one trained algorithm,
+    by means of a corresponding graph, comprising said variables as nodes and comprising
+    topological connections oriented between nodes corresponding to variables among
+    which a probabilistic conditional dependence is identified. In the graph, given
+    a node, the connections entering it show a conditional probability of the value
+    assumed by the variable associated with such node, in a given prediction time,
+    depending on the values assumed, in a prior prediction time, from the variables
+    associated with the nodes from which such connections originate. The method further
+    comprises the steps of entering, for each of the defined variables, data acquired
+    at a given acquisition time relating to the situation of a specific patient; and
+    calculating, by electronic processing and/or calculating means, on the basis of
+    the Dynamic Bayesian Network and the graph, and starting from the aforesaid acquired
+    data, the values of each of the defined variables, at one or more prediction times
+    following the acquisition time. Finally, the method involves obtaining, in a given
+    prediction time, disease progression prognosis results on the basis of the values
+    of one or more of the variables of the third group calculated in such prediction
+    time; and the survival prognosis results on the basis of the value of at least
+    one variable associated with survival, calculated at such prediction time.
+
+
+    Business Description: The invention relates to a new probabilistic model based
+    on dynamic Bayesian networks: by introducing specific clinical data of patients
+    suffering from amyotrophic lateral sclerosis (ALS), the model object of the invention
+    allows to predict the course of the disease, the loss of autonomy in specific
+    functional domains and the survival, and to identify risk factors of the disease.
+
+
+    Tech Features: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease,
+    characterized by progressive muscle paralysis caused by motor neuron degeneration.
+    The onset and progression of ALS are very heterogeneous, making the development
+    of personalised approaches extremely difficult. The invention consists of a probabilistic
+    predictor of ALS progression, based on a dynamic Bayesian network built using
+    a database of over 4000 patients treated at specialised centres in Italy and Israel.
+    By intoducing the clinical information of a new ALS subject, the invention allows
+    to simulate the clinical course and to probabilistically predict the risk of impairment
+    of the functional domains typical of ALS and the survival, representing an important
+    tool to support clinical decision-making and the drafting of the treatment plan.
+
+
+    Applications: Online platform (SaaS)/software for predicting ALS progression;
+    Support to clinical decision and drafting of the treatment plan; Institutional
+    stakeholder decision support; In silico generation of patient populations with
+    specific characteristics.
+
+
+    Advantages: Prediction of ALS progression; Personalized medicine approach; Clinical
+    decision support; Identification of new prognostic markers; Possible alternative
+    to placebo cohorts in clinical trials.'
+  - "COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN FOR USE IN TREATMENT OF BONE\
+    \ DISEAS. Title: COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN FOR USE IN\
+    \ TREATMENT OF BONE DISEAS\n\nAbstract: \n\nBusiness Description: The patent concerns\
+    \ the possible use of polydatin for the treatment of pathologies characterized\
+    \ by reduced bone mass. Polydatin is an oligostilbene that can be extracted in\
+    \ abundant quantities from the roots of the Polygonum Cuspidatum plant and, according\
+    \ to our studies about osteoblastic proliferation and differentiation, is able\
+    \ to increase osteogenic activity.\n\nTech Features: Skeletal pathologies are\
+    \ widespread in the world population, more than 200 million people are osteoporosis\
+    \ patients and have a high probability of fracture. Polydatin is a substance of\
+    \ natural origin, free of the side effects related to the use of synthetic drugs, currently\
+    \ administered for the treatment of bone loss diseases . Our experiments carried\
+    \ out in two-dimensional cultures (2D) and in cells grown on Scaffold (3D), have\
+    \ shown that polydatin is able to increase the activity of osteoblasts (ALP) and\
+    \ the deposition of Bone Matrix. The compositions comprising or consisting of\
+    \ polydatin may be administered orally (for example capsules or tablets, solutions,\
+    \ emulsions) or topically (oils, creams, ointments), or even through an appropriate\
+    \ enrichment of the active ingredient in functional foods\n\nApplications: Patients\
+    \ with traumatic-degenerative pathologies of the skeleton and oral cavity; Osteoporosis\
+    \ patients;\n\nAdvantages: Molecule of natural origin; Antioxidant activity on\
+    \ the whole organism; Possibility of topical use;"
+- source_sentence: "OFFLOADNN. Title: OFFLOADNN\n\nAbstract: \n\nBusiness Description:\
+    \ Resource availability at the edge is generally limited, with particular regard\
+    \ to memory consumption of DNNs, rarely considered as a limiting factor to the\
+    \ execution of tasks at the edge. Furthermore, the structure of the DNNs required\
+    \ for different CV inference tasks and the correlation among them have often been\
+    \ overlooked. Accounting for all this, the invention decreases the resource consumption\
+    \ of DNNs dedicated to run CV tasks, which in turn allow to run more tasks or\
+    \ to decrease the energy consumption with the same number of running tasks.\n\n\
+    Tech Features: The invention is OffloaDNN, a framework to support the scalable\
+    \ offloading of computer vision (CV) tasks to the edge. We formulated the problem\
+    \ of DNN for scalable Offloading of Tasks (DOT) to find the optimal configuration\
+    \ of the DNN, the tasks that can be admitted and the allocation of compute and\
+    \ network resources to assign to the tasks. DOT minimizes the task rejection rate\
+    \ and resource consumption, while meeting the accuracy and latency requirements\
+    \ of admitted tasks. As the DOT is NP-hard, and therefore complex to solve to\
+    \ optimality, OffloaDNN solves the DOT efficiently using a weighted tree-based\
+    \ graph modeling of the feasible solutions. The invention allows to decrease the\
+    \ resources needed at the edge, also allowing for multiple task execution when\
+    \ these require the same DNN components. The lowering of resources needed implies\
+    \ also a lower energy consumption with operational savings.\n\nApplications: Computer\
+    \ vision tasks using edge computing.\n\nAdvantages: Lower resources needed at\
+    \ the edge; Lower energy consumption; Lower operative costs."
   sentences:
-  - Device for the collection and analysis of a biological fluid.
-  - STED MICROSCOPY BASED ON SYNCHRONOUS DETECTION OF FLUORESCENCE EMISSION.
-  - Robotic apparatus for minimally invasive surgery.
-- source_sentence: Method for obtaining a porous semiconductor.
+  - "OFFLOADNN. Title: OFFLOADNN\n\nAbstract: \n\nBusiness Description: Resource availability\
+    \ at the edge is generally limited, with particular regard to memory consumption\
+    \ of DNNs, rarely considered as a limiting factor to the execution of tasks at\
+    \ the edge. Furthermore, the structure of the DNNs required for different CV inference\
+    \ tasks and the correlation among them have often been overlooked. Accounting\
+    \ for all this, the invention decreases the resource consumption of DNNs dedicated\
+    \ to run CV tasks, which in turn allow to run more tasks or to decrease the energy\
+    \ consumption with the same number of running tasks.\n\nTech Features: The invention\
+    \ is OffloaDNN, a framework to support the scalable offloading of computer vision\
+    \ (CV) tasks to the edge. We formulated the problem of DNN for scalable Offloading\
+    \ of Tasks (DOT) to find the optimal configuration of the DNN, the tasks that\
+    \ can be admitted and the allocation of compute and network resources to assign\
+    \ to the tasks. DOT minimizes the task rejection rate and resource consumption,\
+    \ while meeting the accuracy and latency requirements of admitted tasks. As the\
+    \ DOT is NP-hard, and therefore complex to solve to optimality, OffloaDNN solves\
+    \ the DOT efficiently using a weighted tree-based graph modeling of the feasible\
+    \ solutions. The invention allows to decrease the resources needed at the edge,\
+    \ also allowing for multiple task execution when these require the same DNN components.\
+    \ The lowering of resources needed implies also a lower energy consumption with\
+    \ operational savings.\n\nApplications: Computer vision tasks using edge computing.\n\
+    \nAdvantages: Lower resources needed at the edge; Lower energy consumption; Lower\
+    \ operative costs."
+  - 'Polymeric endodontic instruments. Title: Polymeric endodontic instruments
+
+
+    Abstract: The present invention relates to an endodontic tool for shaping a dental
+    root canal, wherein said tool comprises a handle (13), a tang (11), and a stem
+    (10) made of polymeric material and comprising a tip (12) and at least one helically
+    developing cutting edge (100), and wherein said stem (10) develops along a longitudinal
+    axis (A-A). The stem (10) has a substantially conical or tapering twisted shape,
+    in particular said stem (10) having a solid cross-section with a diameter increasing
+    from the tip (12) to the tang (11).
+
+
+    Business Description: Endodontic files for shaping canal roots are made of Ni-Ti
+    alloy or stainless steel. Production, based on precision micromechanics processes,
+    involves high costs and time. Production limitations affect the geometries, especially
+    near the tip, reducing cutting efficiency. Another critical issue is the potential
+    failure of the instrument during treatment, which can trap it in the canal and
+    require invasive procedures for the patient.
+
+
+    Tech Features: The analysis of materials databases has identified families of
+    biocompatible polymers, potentially reinforced, capable of sustaining the applied
+    loads even better than the traditional metallic materials used for endodontic
+    files. The selected polymers offer advantages in terms of fatigue resistance and
+    reduced costs. However, they present critical issues related to hardness and torsion
+    resistance, which are fundamental characteristics for the shaping of the canal
+    root. To address these issues, the use of biocompatible surface coatings with
+    high hardness and low friction coefficient is proposed, applicable through technologies
+    such as chemical vapor deposition. These coatings can significantly improve the
+    surface resistance of polymers, making them suitable for use in endodontic files.
+
+
+    Applications: Biocompatible polymers have been identified that withstand critical
+    stresses leading to the failure of metallic tools during canal shaping; The identified
+    polymers, with lower density and cost compared to metals, allow the use of inexpensive
+    mass production technologies.
+
+
+    Advantages: Drastic reduction in production costs; Reduction or elimination of
+    the risk of instrument failure in the canal; Creation of innovative geometries
+    through 3D printing or injection molding for large-scale production.'
+  - 'Unidirectional mechanical device. Title: Unidirectional mechanical device
+
+
+    Abstract: Unidirectional mechanical device comprising at least one array (10;
+    20) of three or more cells (100; 200). Each cell (100; 200) of the array comprises:
+    a floating mass (101; 201); at least one first elastic element (102; 202) connecting
+    the floating mass (101; 201) to a reference external structure for the unidirectional
+    mechanical device, wherein the at least one first elastic element (102; 202) comprises
+    at least one first folded beam; at least one second elastic element (103) connecting
+    the floating mass (101) to a second floating mass of a preceding cell of the at
+    least one array (10), wherein the at least one second elastic element (103) comprises
+    at least one second folded beam; at least one third elastic element (104) connecting
+    the floating mass (101) to a third floating mass of a succeeding cell of the at
+    least one array (10), wherein the at least one third elastic element (104) comprises
+    at least one third folded beam; an electric system configured to control a potential
+    difference acting on the floating mass (101; 201), determining an overall electrostatic
+    stiffness of the at least one array (10; 20).
+
+
+    Business Description: The invention consists of a mono-directional mechanical
+    filter at a micrometric scale, which can be integrated into MEMS systems. In certain
+    frequency bands, the device allows the propagation of mechanical waves in only
+    one direction, blocking those travelling in the opposite direction. We obtain
+    this filter by means of a periodic structure with time-modulated stiffness, here
+    achieved by regulating suitable voltages.
+
+
+    Tech Features: In mechanics, the principle of reciprocity dictates that a system
+    excited at point A and observed at point B behaves in the same way if excited
+    at B and observed at A. One of the ways to create a non-reciprocal system is to
+    break temporal invariance. A substantial number of scientific works in recent
+    years have dealt with the theoretical and experimental description of these systems,
+    created through periodic structures of time-varying stiffness. However, these
+    works remain confined to the level of speculation and demonstrative prototypes
+    to the macro-scale, with complicated and difficult to implement solutions. The
+    present invention realizes the above principles in an easy-to-produce MEMS device
+    by using an electrostatic principle for the modulation of the stiffness which,
+    since it is not present at the macro-scale but only at the micro-scale, had not
+    been considered with this aim up to now. Essentially, the system is made up of
+    the repetition of some elementary cells, made up of springs and masses that house
+    an electrode with parallel faces for modulation. We speculate that this new type
+    of system can be used both as a new sensor and/or as a component (e.g. filter)
+    in more complex systems.
+
+
+    Applications: MEMS directional sensor; Directional filter for devices that use
+    elastic waves as the main means of transduction.
+
+
+    Advantages: Uses mechanical waves; Mechanical device with non-symmetrical response
+    (equivalent of an electric diode); Lower frequencies as compared to electromagnetic
+    waves; Can be manufactured using traditional MEMS technologies.'
+- source_sentence: "GEL FORMULATION FOR THE ORAL ADMINISTRATION OF DRUGS IN PARTICULAR\
+    \ TO DYSPHAGIC PATIENTS. Title: GEL FORMULATION FOR THE ORAL ADMINISTRATION OF\
+    \ DRUGS IN PARTICULAR TO DYSPHAGIC PATIENTS\n\nAbstract: \n\nBusiness Description:\
+    \ The present invention relates to a gel formulation containing water-soluble\
+    \ active ingredients mainly available on the pharmaceutical market as oral solid\
+    \ dosage forms such as immediate-release tablets or capsules or powders or granules\
+    \ for oral use. The formulation object of the present invention satisfies the\
+    \ particular needs of patients who show anomalies in the swallowing process. The\
+    \ pathological condition related to swallowing problems is called dysphagia.\n\
+    \nTech Features: The present invention provides a method for reformulating water-soluble\
+    \ drugs, when commercially available for oral administration only in solid form\
+    \ with immediate release, mostly tablets and / or capsules without neglecting\
+    \ the existence of granules and powders for oral use. Drugs are reformulated as\
+    \ semi-solid preparations suitable for oral administration in patients with swallowing.\
+    \ This method allows to obtain an unchanged release of the active ingredient,\
+    \ compared to that of the drug formulated in the original dosage form. The present\
+    \ patent therefore describes a semi-solid formulation with rheological characteristics\
+    \ comparable to commercially gelled drinks, used for hydration and the administration\
+    \ of therapy to patients with swallowing disorders.\n\nApplications: Avoid any\
+    \ handling operations by eliminating the dangers associated with loss of active\
+    \ substance; Avoid contamination and dosage errors with greater safety in the\
+    \ administration of drugs; The active substance is formulated in a dosage form\
+    \ with a consistency suitable for swallowing in the dysphagic patients without\
+    \ its release kinetics being altered.\n\nAdvantages: Potential applicability in\
+    \ hospital pharmacies to standardize, optimize and automate the galenic preparations\
+    \ of drugs available only as tablets; Large-scale marketing can improve the therapeutic\
+    \ possibilities for dysphagia patients; Industrial production may cover a market\
+    \ share, which is currently entrusted to galenic production in a pharmacy."
   sentences:
-  - 'Racetrack Logic: smart in-memory computing.'
-  - Method for obtaining a porous semiconductor.
-  - Salts of benzimidazole compounds, their use and synthetic preparation.
-- source_sentence: Enthalpy exchangers with polymeric membrane.
+  - "Supplement for psychiatric disorders. Title: Supplement for psychiatric disorders\n\
+    \nAbstract: \n\nBusiness Description: The present invention relates to an ester\
+    \ of a phospholipid with conjugated linoleic acid (CLA) as a nutritional supplement\
+    \ in treatment of psychiatric disorders with neuroinflammatory and neurodegenerative\
+    \ basis, such as depression, bipolar disorder and schizophrenia.\n\nTech Features:\
+    \ The search for alternative therapies in place of non-steroidal anti-inflammatory\
+    \ drugs for neuroinflammation is crucial since the risk of side effects derived\
+    \ from their use has been demonstrated especially during pregnancy with serious\
+    \ outcomes such as the development of sexual organs in the fetus as well as subsequent\
+    \ psychiatric trajectory in the offspring life in both sexes. Therefore, an alternative\
+    \ therapeutic approach would be resolutive to pharmacological treatment. We have\
+    \ shown in in-vivo models that the dietary intake of 0.5% CLA (i) increases omega-3\
+    \ DHA fatty acid levels by approx. 10 times in both the maternal and fetal liver,\
+    \ and approx. 5 times in the fetal brain; (ii) increases gene expression of PPAR\
+    \ alpha and its PEA and OEA ligands. These molecules are known to exert a potent\
+    \ anti-neuroinflammatory activity and thereby a protective effect against those\
+    \ psychiatric disorders with neuroinflammatory basis. Furthermore, as ester of\
+    \ a phospholipid the bioavailability of CLA is increased.\nTRL= 3 - 4 ( in-vivo\
+    \ )\n\nApplications: Psychiatric disorders with neuroinflammatory basis such as\
+    \ depression, bipolar disorder and schizophrenia.\n\nAdvantages: Absence of side\
+    \ effects; Suitable also during critical windows of vulnerability such as pregnancy\
+    \ and infancy; CLA can be formulated as a functional food, facilitating its compliance."
+  - "Safepack: Safety Backpack for riders. Title: Safepack: Safety Backpack for riders\n\
+    \nAbstract: \n\nBusiness Description: Safepack is the first smart backpack designed\
+    \ for Gig Economy delivery service riders. It is fully integrated into the work\
+    \ dynamics and improves user safety by reducing the possibility of distraction\
+    \ and enhancing communication with other road users.\n\nTech Features: Safepack\
+    \ consists of: 1) Tactile navigation system, inserted in the belt, consisting\
+    \ of piezoelectric actuators that vibrate in the direction of the path to follow\
+    \ and an inflation system that ensures the fitting and correct perception of the\
+    \ vibration. 2) Communication system based on voice interface (Speaker and microphone):\
+    \ the rider can receive information from the platform, such as the delivery of\
+    \ a new order (collection / delivery point, distance, compensation), can accept\
+    \ or reject it and communicate delays or emergencies. 3) Automatic lighting system,\
+    \ aimed at improving communication with other road users. The light is generated\
+    \ by side-emitting optical fibers connected to a yellow LED for the visibility\
+    \ lights, and red LEDs for the directional and brake lights. Finally, Safepack\
+    \ communicates via bluetooth with the platform app and with the navigation app.\
+    \ The volume of the voice interface and the intensity of the vibration can be\
+    \ adjusted thanks to a pressure sensor placed in the right shoulder strap.\n\n\
+    Applications: Riders working in Gig economy delivery services.\n\nAdvantages:\
+    \ A smart product perfectly integrated into the working dynamics of the delivery\
+    \ platforms; Offers a support tool that allows a rider not to have to constantly\
+    \ look at a smartphone to receive navigation instructions and information from\
+    \ the platform app; Improves rider safety by reducing distracting factors, making\
+    \ him visible and communicating his movements to other road users."
+  - "GEL FORMULATION FOR THE ORAL ADMINISTRATION OF DRUGS IN PARTICULAR TO DYSPHAGIC\
+    \ PATIENTS. Title: GEL FORMULATION FOR THE ORAL ADMINISTRATION OF DRUGS IN PARTICULAR\
+    \ TO DYSPHAGIC PATIENTS\n\nAbstract: \n\nBusiness Description: The present invention\
+    \ relates to a gel formulation containing water-soluble active ingredients mainly\
+    \ available on the pharmaceutical market as oral solid dosage forms such as immediate-release\
+    \ tablets or capsules or powders or granules for oral use. The formulation object\
+    \ of the present invention satisfies the particular needs of patients who show\
+    \ anomalies in the swallowing process. The pathological condition related to swallowing\
+    \ problems is called dysphagia.\n\nTech Features: The present invention provides\
+    \ a method for reformulating water-soluble drugs, when commercially available\
+    \ for oral administration only in solid form with immediate release, mostly tablets\
+    \ and / or capsules without neglecting the existence of granules and powders for\
+    \ oral use. Drugs are reformulated as semi-solid preparations suitable for oral\
+    \ administration in patients with swallowing. This method allows to obtain an\
+    \ unchanged release of the active ingredient, compared to that of the drug formulated\
+    \ in the original dosage form. The present patent therefore describes a semi-solid\
+    \ formulation with rheological characteristics comparable to commercially gelled\
+    \ drinks, used for hydration and the administration of therapy to patients with\
+    \ swallowing disorders.\n\nApplications: Avoid any handling operations by eliminating\
+    \ the dangers associated with loss of active substance; Avoid contamination and\
+    \ dosage errors with greater safety in the administration of drugs; The active\
+    \ substance is formulated in a dosage form with a consistency suitable for swallowing\
+    \ in the dysphagic patients without its release kinetics being altered.\n\nAdvantages:\
+    \ Potential applicability in hospital pharmacies to standardize, optimize and\
+    \ automate the galenic preparations of drugs available only as tablets; Large-scale\
+    \ marketing can improve the therapeutic possibilities for dysphagia patients;\
+    \ Industrial production may cover a market share, which is currently entrusted\
+    \ to galenic production in a pharmacy."
+- source_sentence: 'TARGETING SMALL RNAS AS A THERAPY FOR ALS. Title: TARGETING SMALL
+    RNAS AS A THERAPY FOR ALS
+
+
+    Abstract: The present invention relates to an inhibitor of miR-129, relative compounds
+    and pharmaceutical compositions for use in the treatment and/or prevention of
+    amyotrophic lateral sclerosis and Alzheimer''s disease. The invention also relates
+    to a method for the diagnosis and/or prognosis of Alzheimer''s disease in a subject
+    or to identify a subject at risk to develop amyotrophic lateral sclerosis or Alzheimer''s
+    disease and to a method for the measuring the efficacy of a therapy for amyotrophic
+    lateral sclerosis or for Alzheimer''s disease and relative kits.
+
+
+    Business Description: We propose to develop a drug product to treat all forms
+    of ALS by targeting an important pathogenic pathway, miR-129-1 that is up-regulated
+    in both familial and sporadic ALS patients, in human and SOD1 G93A mice (A-B).
+    Antisense technology is entering a phase of clinical successes and we believe
+    that our strategy can provide clinically meaningful benefit to patients that have
+    no therapeutic hope. To date, current approved treatments for ALS, which at best
+    guarantee a span life extension of 3 months, are riluzole (Li et al., Plos One
+    2013) and edaravone (Ito et al, Exp Neurol, 2008) .
+
+
+    Tech Features: Our proposed miR-129-1 PMO therapeutic strategy outperformed when
+    compared with these ALS approved molecules. Our patented a miR-129-1 modulation
+    strategy with a Morpholino Antisense Oligonucleotide (ASO-PMO) and demonstrated
+    in vivo that it recovers the expression of its target protein HuD, allowing for
+    a 12.5% ​​increase in survival and an improvement neuromuscular performance of
+    SOD1 G93A mice, a genetic model of ALS, treated in the pre-symptomatic phase. To
+    improve miR-129-1 PMO therapeutic efficacy, better delivery to target tissue is
+    needed: based on our experimental data from another study on motor neuron disease,
+    an arginine-rich peptide conjugated with PMO (CPP-PMO) shows an increased efficacy
+    in vivo . In addition, the mouse model TDP43 can be used to demonstrate a more
+    general efficacy of the product, before proceeding with toxicological and pharmacokinetic
+    evaluation in the preclinical setting. In addition, the mouse model TDP43 can
+    be used to demonstrate a more general efficacy of the product, before proceeding
+    with toxicological and pharmacokinetic evaluation in the preclinical setting.
+
+
+    Applications: Familial amyotrophic lateral sclerosis, Sporadic amyotrophic lateral
+    sclerosis, Alzheimer Disease, Epilepsy, Fragile X syndrome, Tubero sclerosis complex
+    and Cornea pathologies.
+
+
+    Advantages: Targeting miRNA allows modulation of a large number of target genes;
+    PMO works as a steric-blocker, a more effective strategy when the target is a
+    miRNA; PMO is superior to small molecules for improved target affinity; PMO fulfills
+    important criteria of solubility, stability, binding affinity, in vitro and in
+    vivo efficacy and in vivo toxicity if compared to other chemistries; PMO has low
+    risk in terms of toxicity, off target effects and immune response stimulation.'
   sentences:
-  - Closure system for engine connecting rods.
-  - Enthalpy exchangers with polymeric membrane.
-  - Soluble protein with high angiogenic activity.
-- source_sentence: FLEXIBLE CAPACITIVE KEYBOARD FOR TEXTILE USE.
+  - 'Antimicrobial dental adhesive graphene-based. Title: Antimicrobial dental adhesive
+    graphene-based
+
+
+    Abstract: Disclosed is a dental adhesive including a polymeric adhesive and a
+    nanofiller dispersed in the polymeric adhesive, the nanofiller being constituted
+    by graphene nanostructures which are properly dispersed inside the polymer adhesive
+    and over the surface of the adhesive layer without formation of agglomerates,
+    so that the dental adhesive exhibits significant antimicrobial and antibiofilm
+    properties against pathogens of the oral cavity.
+
+
+    Business Description: The patent is based on a dental adhesive with antimicrobial
+    and anti-biofilm properties taking advantage of the use of graphene-based micro
+    and nanometer fillers. The nanomaterials introduced into an adhesive are uniformly
+    dispersed, without agglomerations inside the polymer and partially exposed over
+    the adhesive surface. These significantly inhibit, by mechanical action, adhesion
+    and bacterial growth.
+
+
+    Tech Features: The adhesive object of the patent consists of a dental adhesive
+    composed of BisGMA, filled with graphene-based nanoplachets (GNP), produced at
+    low cost by thermal expansion, or its derivatives incorporated in the polymer
+    matrix. Adhesives have strong antimicrobial properties against the bacteria that
+    typically populate the oral cavity, such as Streptococcus mutants. Current commercial
+    adhesives use nanometric fillers, in particular barium glass, zirconium oxide,
+    aluminum oxide, or silicon dioxide, for the sole purpose of increasing the micromechanical
+    adhesion between the adhesive and dentin or enamel, and therefore typically do
+    not have specific properties. antimicrobials. The antimicrobial dental adhesives
+    used have limitations, as organic fillers tend to worsen the mechanical characteristics
+    of dental materials. In fact, these fillers are subject to shrinkage after the
+    cure and polymerization phase, just like the matrix and therefore limit the mechanical
+    strength of the composite.
+
+
+    Applications: Dental adhesive with antimicrobial properties.
+
+
+    Advantages: The particular production process of the new adhesive possess antimicrobial
+    properties; The production of this adhesive does not require structural changes
+    to companies producing dental adhesives; GNP possess the properties of the basal
+    plane typical of 2D graphene, at a lower cost and without its technological problems.
+    Moreover they can be used on a large scale.'
+  - "OXYSTEROL FOR THE TREATMENT AND PREVENTION OF CORONAVIRUS DISEASES. Title: OXYSTEROL\
+    \ FOR THE TREATMENT AND PREVENTION OF CORONAVIRUS DISEASES\n\nAbstract: \n\nBusiness\
+    \ Description: The invention aims to provide antiviral compounds for the prevention\
+    \ and treatment of infections caused by a coronavirus, particularly by SARS-CoV-2.\
+    \ The invention shows that 27-hydroxycholesterol can activate the innate immune\
+    \ response and induce the response of cells and tissues. Formulated in a pharmaceutical\
+    \ composition, it significantly inhibits the infectivity of SARS-CoV-2 (100% at\
+    \ the highest doses).\n\nTech Features: An oxysterol called 27-hydroxycholesterol\
+    \ (27OHC), a derivative of cholesterol obtained by oxidation, endogenous, that\
+    \ is, produced naturally by the human body, has been identified as an antiviral\
+    \ compound. In fact,  in vitro tests, 27OHC was administered after inoculating\
+    \ susceptible cells with SARS-CoV-2, simulating a viral infection treatment protocol.\
+    \ 27OHC was able to inhibit the replication of SARS-CoV-2 and other human coronavirus\
+    \ that causes the common cold (HCoV-OC43), without cytotoxicity, at concentrations\
+    \ in the micromolar range.\n\nThis study has been published on the journal Redox\
+    \ Biology and is available ( https://doi.org/10.1016/j.redox.2020.101682 ).\n\n\
+    Applications: Pharmaceutical sector; Respiratory diseases; Chronic inflammatory\
+    \ gastrointestinal diseases.\n\nAdvantages: New treatment for SARS-CoV-2; Treatment\
+    \ active against other Coronaviruses; Physiological drug naturally present in\
+    \ the human organism."
+  - 'TARGETING SMALL RNAS AS A THERAPY FOR ALS. Title: TARGETING SMALL RNAS AS A THERAPY
+    FOR ALS
+
+
+    Abstract: The present invention relates to an inhibitor of miR-129, relative compounds
+    and pharmaceutical compositions for use in the treatment and/or prevention of
+    amyotrophic lateral sclerosis and Alzheimer''s disease. The invention also relates
+    to a method for the diagnosis and/or prognosis of Alzheimer''s disease in a subject
+    or to identify a subject at risk to develop amyotrophic lateral sclerosis or Alzheimer''s
+    disease and to a method for the measuring the efficacy of a therapy for amyotrophic
+    lateral sclerosis or for Alzheimer''s disease and relative kits.
+
+
+    Business Description: We propose to develop a drug product to treat all forms
+    of ALS by targeting an important pathogenic pathway, miR-129-1 that is up-regulated
+    in both familial and sporadic ALS patients, in human and SOD1 G93A mice (A-B).
+    Antisense technology is entering a phase of clinical successes and we believe
+    that our strategy can provide clinically meaningful benefit to patients that have
+    no therapeutic hope. To date, current approved treatments for ALS, which at best
+    guarantee a span life extension of 3 months, are riluzole (Li et al., Plos One
+    2013) and edaravone (Ito et al, Exp Neurol, 2008) .
+
+
+    Tech Features: Our proposed miR-129-1 PMO therapeutic strategy outperformed when
+    compared with these ALS approved molecules. Our patented a miR-129-1 modulation
+    strategy with a Morpholino Antisense Oligonucleotide (ASO-PMO) and demonstrated
+    in vivo that it recovers the expression of its target protein HuD, allowing for
+    a 12.5% ​​increase in survival and an improvement neuromuscular performance of
+    SOD1 G93A mice, a genetic model of ALS, treated in the pre-symptomatic phase. To
+    improve miR-129-1 PMO therapeutic efficacy, better delivery to target tissue is
+    needed: based on our experimental data from another study on motor neuron disease,
+    an arginine-rich peptide conjugated with PMO (CPP-PMO) shows an increased efficacy
+    in vivo . In addition, the mouse model TDP43 can be used to demonstrate a more
+    general efficacy of the product, before proceeding with toxicological and pharmacokinetic
+    evaluation in the preclinical setting. In addition, the mouse model TDP43 can
+    be used to demonstrate a more general efficacy of the product, before proceeding
+    with toxicological and pharmacokinetic evaluation in the preclinical setting.
+
+
+    Applications: Familial amyotrophic lateral sclerosis, Sporadic amyotrophic lateral
+    sclerosis, Alzheimer Disease, Epilepsy, Fragile X syndrome, Tubero sclerosis complex
+    and Cornea pathologies.
+
+
+    Advantages: Targeting miRNA allows modulation of a large number of target genes;
+    PMO works as a steric-blocker, a more effective strategy when the target is a
+    miRNA; PMO is superior to small molecules for improved target affinity; PMO fulfills
+    important criteria of solubility, stability, binding affinity, in vitro and in
+    vivo efficacy and in vivo toxicity if compared to other chemistries; PMO has low
+    risk in terms of toxicity, off target effects and immune response stimulation.'
+- source_sentence: "High reduction and backdrivability ACTUATion SYSTEM with minimal\
+    \ lateral encumbrance. Title: High reduction and backdrivability ACTUATion SYSTEM\
+    \ with minimal lateral encumbrance\n\nAbstract: \n\nBusiness Description: Typical\
+    \ robotic actuation units have a motor and its transmission system aligned with\
+    \ the axis of the joint they actuate, resulting in large lateral encumbrance of\
+    \ the whole system.\n\nThis solution aims at solving this problem and allows to\
+    \ locate the last transmission stage at an arbitrary distance from the axis of\
+    \ the screw.\n\nTech Features: This invention consists in a class of actuation\
+    \ systems which is specifically designed to minimize the lateral encumbrance of\
+    \ the exoskeletal system to maximize its practical usability. Its core components\
+    \ are a motor coupled to a leadscrew or ballscrew system and a further (arbitrary)\
+    \ transmission system to connect the nut of the screw based transmission to the\
+    \ output wheel.\n\nFurthermore, this solution allows to displace the location\
+    \ of the screw with respect to the final transmission stage, allowing the adaptation\
+    \ of the location of the different stages of the system without influencing the\
+    \ overall behavior.The designed anti-blockage system guarantees proper functioning\
+    \ of each mechanical component and high back-drivability of the overall system\
+    \ even for high overall gearing.\n\nApplications: Robotics.\n\nAdvantages: Minimal\
+    \ lateral encumbrance; High gearing; Highly Back-drivable; Torque estimation through\
+    \ current measurement; Capability of dislocating the screw from the point of application\
+    \ of force."
   sentences:
-  - 'GreenValve III: System for spherical segment valves.'
-  - FLEXIBLE CAPACITIVE KEYBOARD FOR TEXTILE USE.
-  - Mandibular advancement device.
+  - "High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance.\
+    \ Title: High reduction and backdrivability ACTUATion SYSTEM with minimal lateral\
+    \ encumbrance\n\nAbstract: \n\nBusiness Description: Typical robotic actuation\
+    \ units have a motor and its transmission system aligned with the axis of the\
+    \ joint they actuate, resulting in large lateral encumbrance of the whole system.\n\
+    \nThis solution aims at solving this problem and allows to locate the last transmission\
+    \ stage at an arbitrary distance from the axis of the screw.\n\nTech Features:\
+    \ This invention consists in a class of actuation systems which is specifically\
+    \ designed to minimize the lateral encumbrance of the exoskeletal system to maximize\
+    \ its practical usability. Its core components are a motor coupled to a leadscrew\
+    \ or ballscrew system and a further (arbitrary) transmission system to connect\
+    \ the nut of the screw based transmission to the output wheel.\n\nFurthermore,\
+    \ this solution allows to displace the location of the screw with respect to the\
+    \ final transmission stage, allowing the adaptation of the location of the different\
+    \ stages of the system without influencing the overall behavior.The designed anti-blockage\
+    \ system guarantees proper functioning of each mechanical component and high back-drivability\
+    \ of the overall system even for high overall gearing.\n\nApplications: Robotics.\n\
+    \nAdvantages: Minimal lateral encumbrance; High gearing; Highly Back-drivable;\
+    \ Torque estimation through current measurement; Capability of dislocating the\
+    \ screw from the point of application of force."
+  - "Fluid filtering device based on a rotating valve pressure exchanger. Title: Fluid\
+    \ filtering device based on a rotating valve pressure exchanger\n\nAbstract: \n\
+    \nBusiness Description: The invention consists of an high pressure reciprocating\
+    \ pumping system equipped with an energy recovery device, intended for reverse\
+    \ osmosis plants. The patented device, descending by previous ENEA's patents,\
+    \ permits to realize water treatment plants with low energy consumption.\n\nTech\
+    \ Features: During ENEA's research in absorption refrigeration machines, have\
+    \ been patented several reciprocating pumping systems based on oil gear pumps\
+    \ coupled with an original self-adjusting rotating valve. Such a coupling, instead\
+    \ of the usual piston-rod-crank kinematic, has permitted to realize low cost and\
+    \ high reliability high pressure reciprocating pumps, called \"VR pumps\". Basing\
+    \ on the original know-how developed for the technology, a new invention has been\
+    \ patented, which consists to link a high pressure primary pump, VR type or not,\
+    \ to a second VR pump acted by the pressure of the waste water coming from the\
+    \ desalination plant, instead by pressurized oil as usual. Such second VR pump\
+    \ acts on the desalination circuit like an innovative pressure exchanger.\n\n\
+    Applications: Reverse osmosis desalination plants; Microfiltration desalination\
+    \ plants.\n\nAdvantages: Low cost; Easy scale up; Suitable for small plants; Low\
+    \ specific energy consumption."
+  - "Mechanical towing for automatic vehicle convoys. Title: Mechanical towing for\
+    \ automatic vehicle convoys\n\nAbstract: \n\nBusiness Description: The patent\
+    \ allows a mechanical coupling between vehicles in order to guarantee the safety\
+    \ and operation of a convoy of even 10 vehicles capable of circulating as if it\
+    \ were a single vehicle. This technology therefore allows a single driver in the\
+    \ head vehicle to automatically control the convoy of vehicles connected, revolutionizing\
+    \ the local transport systems with transport services that would otherwise not\
+    \ be feasible.\n\nTech Features: The patented mobile mechanical connection couples\
+    \ two vehicles and transforms them into a convoy that moves like a single unit.\
+    \ By means of an automatic guidance system, the coupled vehicles are able to synchronize\
+    \ automatically with the movements of the head vehicle, ensuring compliance with\
+    \ the trajectory of the head vehicle. The mechanical connection also acts as a\
+    \ safeguard in case of malfunctions and motion \"harmonizer\". This system allows\
+    \ single vehicles to form convoys driven by the driver only on the leading vehicle:\
+    \ free-flow car-sharing vehicles can be relocated from areas where they would\
+    \ be stationed for a long time to areas where there is demand, forming a convoy\
+    \ also of 10 vehicles and moving them with one driver; buses can be extended for\
+    \ the central sections of the transport lines with the highest demand without\
+    \ increasing the drivers; transport systems can be created in which small buses\
+    \ gather people on call in the suburbs and form a single convoy that crosses the\
+    \ center with a single driver. The patented coupling mechanism allows passenger\
+    \ transport companies to re-organize their services by means of convoys of vehicles\
+    \ which combine the maintenance of the optimum passenger capacity and the social\
+    \ requirements imposed by pandemic of COVID-19 and the containment measures taken.\n\
+    \nApplications: Car-sharing services; Logistics and goods distribution companies;\
+    \ Public and private transport with variable capacity.\n\nAdvantages: Certified\
+    \ transport system; Responsible automation; Flexible and client-oriented transport\
+    \ system; Efficiency of transport and sharing systems; Management cost reduction,\
+    \ creating capillary and high capacity services."
 pipeline_tag: sentence-similarity
 library_name: sentence-transformers
+metrics:
+- cosine_accuracy@1
+- cosine_accuracy@3
+- cosine_accuracy@5
+- cosine_accuracy@10
+- cosine_precision@1
+- cosine_precision@3
+- cosine_precision@5
+- cosine_precision@10
+- cosine_recall@1
+- cosine_recall@3
+- cosine_recall@5
+- cosine_recall@10
+- cosine_ndcg@10
+- cosine_mrr@10
+- cosine_map@100
+model-index:
+- name: SentenceTransformer based on AI-Growth-Lab/PatentSBERTa
+  results:
+  - task:
+      type: information-retrieval
+      name: Information Retrieval
+    dataset:
+      name: mnrl val
+      type: mnrl-val
+    metrics:
+    - type: cosine_accuracy@1
+      value: 0.039440203562340966
+      name: Cosine Accuracy@1
+    - type: cosine_accuracy@3
+      value: 0.08778625954198473
+      name: Cosine Accuracy@3
+    - type: cosine_accuracy@5
+      value: 0.14122137404580154
+      name: Cosine Accuracy@5
+    - type: cosine_accuracy@10
+      value: 0.2035623409669211
+      name: Cosine Accuracy@10
+    - type: cosine_precision@1
+      value: 0.039440203562340966
+      name: Cosine Precision@1
+    - type: cosine_precision@3
+      value: 0.029262086513994912
+      name: Cosine Precision@3
+    - type: cosine_precision@5
+      value: 0.028244274809160308
+      name: Cosine Precision@5
+    - type: cosine_precision@10
+      value: 0.020356234096692113
+      name: Cosine Precision@10
+    - type: cosine_recall@1
+      value: 0.039440203562340966
+      name: Cosine Recall@1
+    - type: cosine_recall@3
+      value: 0.08778625954198473
+      name: Cosine Recall@3
+    - type: cosine_recall@5
+      value: 0.14122137404580154
+      name: Cosine Recall@5
+    - type: cosine_recall@10
+      value: 0.2035623409669211
+      name: Cosine Recall@10
+    - type: cosine_ndcg@10
+      value: 0.10853541428278174
+      name: Cosine Ndcg@10
+    - type: cosine_mrr@10
+      value: 0.07969071852659648
+      name: Cosine Mrr@10
+    - type: cosine_map@100
+      value: 0.08979593108601017
+      name: Cosine Map@100
 ---
 
 # SentenceTransformer based on AI-Growth-Lab/PatentSBERTa
@@ -88,9 +767,9 @@ from sentence_transformers import SentenceTransformer
 model = SentenceTransformer("sentence_transformers_model_id")
 # Run inference
 sentences = [
-    'FLEXIBLE CAPACITIVE KEYBOARD FOR TEXTILE USE.',
-    'FLEXIBLE CAPACITIVE KEYBOARD FOR TEXTILE USE.',
-    'GreenValve III: System for spherical segment valves.',
+    'High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance. Title: High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance\n\nAbstract: \n\nBusiness Description: Typical robotic actuation units have a motor and its transmission system aligned with the axis of the joint they actuate, resulting in large lateral encumbrance of the whole system.\n\nThis solution aims at solving this problem and allows to locate the last transmission stage at an arbitrary distance from the axis of the screw.\n\nTech Features: This invention consists in a class of actuation systems which is specifically designed to minimize the lateral encumbrance of the exoskeletal system to maximize its practical usability. Its core components are a motor coupled to a leadscrew or ballscrew system and a further (arbitrary) transmission system to connect the nut of the screw based transmission to the output wheel.\n\nFurthermore, this solution allows to displace the location of the screw with respect to the final transmission stage, allowing the adaptation of the location of the different stages of the system without influencing the overall behavior.The designed anti-blockage system guarantees proper functioning of each mechanical component and high back-drivability of the overall system even for high overall gearing.\n\nApplications: Robotics.\n\nAdvantages: Minimal lateral encumbrance; High gearing; Highly Back-drivable; Torque estimation through current measurement; Capability of dislocating the screw from the point of application of force.',
+    'High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance. Title: High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance\n\nAbstract: \n\nBusiness Description: Typical robotic actuation units have a motor and its transmission system aligned with the axis of the joint they actuate, resulting in large lateral encumbrance of the whole system.\n\nThis solution aims at solving this problem and allows to locate the last transmission stage at an arbitrary distance from the axis of the screw.\n\nTech Features: This invention consists in a class of actuation systems which is specifically designed to minimize the lateral encumbrance of the exoskeletal system to maximize its practical usability. Its core components are a motor coupled to a leadscrew or ballscrew system and a further (arbitrary) transmission system to connect the nut of the screw based transmission to the output wheel.\n\nFurthermore, this solution allows to displace the location of the screw with respect to the final transmission stage, allowing the adaptation of the location of the different stages of the system without influencing the overall behavior.The designed anti-blockage system guarantees proper functioning of each mechanical component and high back-drivability of the overall system even for high overall gearing.\n\nApplications: Robotics.\n\nAdvantages: Minimal lateral encumbrance; High gearing; Highly Back-drivable; Torque estimation through current measurement; Capability of dislocating the screw from the point of application of force.',
+    'Mechanical towing for automatic vehicle convoys. Title: Mechanical towing for automatic vehicle convoys\n\nAbstract: \n\nBusiness Description: The patent allows a mechanical coupling between vehicles in order to guarantee the safety and operation of a convoy of even 10 vehicles capable of circulating as if it were a single vehicle. This technology therefore allows a single driver in the head vehicle to automatically control the convoy of vehicles connected, revolutionizing the local transport systems with transport services that would otherwise not be feasible.\n\nTech Features: The patented mobile mechanical connection couples two vehicles and transforms them into a convoy that moves like a single unit. By means of an automatic guidance system, the coupled vehicles are able to synchronize automatically with the movements of the head vehicle, ensuring compliance with the trajectory of the head vehicle. The mechanical connection also acts as a safeguard in case of malfunctions and motion "harmonizer". This system allows single vehicles to form convoys driven by the driver only on the leading vehicle: free-flow car-sharing vehicles can be relocated from areas where they would be stationed for a long time to areas where there is demand, forming a convoy also of 10 vehicles and moving them with one driver; buses can be extended for the central sections of the transport lines with the highest demand without increasing the drivers; transport systems can be created in which small buses gather people on call in the suburbs and form a single convoy that crosses the center with a single driver. The patented coupling mechanism allows passenger transport companies to re-organize their services by means of convoys of vehicles which combine the maintenance of the optimum passenger capacity and the social requirements imposed by pandemic of COVID-19 and the containment measures taken.\n\nApplications: Car-sharing services; Logistics and goods distribution companies; Public and private transport with variable capacity.\n\nAdvantages: Certified transport system; Responsible automation; Flexible and client-oriented transport system; Efficiency of transport and sharing systems; Management cost reduction, creating capillary and high capacity services.',
 ]
 embeddings = model.encode(sentences)
 print(embeddings.shape)
@@ -99,9 +778,9 @@ print(embeddings.shape)
 # Get the similarity scores for the embeddings
 similarities = model.similarity(embeddings, embeddings)
 print(similarities)
-# tensor([[1.0000, 1.0000, 0.3686],
-#         [1.0000, 1.0000, 0.3686],
-#         [0.3686, 0.3686, 1.0000]])
+# tensor([[1.0000, 1.0000, 0.5066],
+#         [1.0000, 1.0000, 0.5066],
+#         [0.5066, 0.5066, 1.0000]])
 ```
 
 <!--
@@ -128,6 +807,33 @@ You can finetune this model on your own dataset.
 *List how the model may foreseeably be misused and address what users ought not to do with the model.*
 -->
 
+## Evaluation
+
+### Metrics
+
+#### Information Retrieval
+
+* Dataset: `mnrl-val`
+* Evaluated with [<code>InformationRetrievalEvaluator</code>](https://sbert.net/docs/package_reference/sentence_transformer/evaluation.html#sentence_transformers.evaluation.InformationRetrievalEvaluator)
+
+| Metric              | Value      |
+|:--------------------|:-----------|
+| cosine_accuracy@1   | 0.0394     |
+| cosine_accuracy@3   | 0.0878     |
+| cosine_accuracy@5   | 0.1412     |
+| cosine_accuracy@10  | 0.2036     |
+| cosine_precision@1  | 0.0394     |
+| cosine_precision@3  | 0.0293     |
+| cosine_precision@5  | 0.0282     |
+| cosine_precision@10 | 0.0204     |
+| cosine_recall@1     | 0.0394     |
+| cosine_recall@3     | 0.0878     |
+| cosine_recall@5     | 0.1412     |
+| cosine_recall@10    | 0.2036     |
+| **cosine_ndcg@10**  | **0.1085** |
+| cosine_mrr@10       | 0.0797     |
+| cosine_map@100      | 0.0898     |
+
 <!--
 ## Bias, Risks and Limitations
 
@@ -146,19 +852,19 @@ You can finetune this model on your own dataset.
 
 #### Unnamed Dataset
 
-* Size: 7,861 training samples
+* Size: 6,288 training samples
 * Columns: <code>sentence_0</code> and <code>sentence_1</code>
 * Approximate statistics based on the first 1000 samples:
-  |         | sentence_0                                                                        | sentence_1                                                                        |
-  |:--------|:----------------------------------------------------------------------------------|:----------------------------------------------------------------------------------|
-  | type    | string                                                                            | string                                                                            |
-  | details | <ul><li>min: 4 tokens</li><li>mean: 12.32 tokens</li><li>max: 32 tokens</li></ul> | <ul><li>min: 8 tokens</li><li>mean: 12.01 tokens</li><li>max: 36 tokens</li></ul> |
+  |         | sentence_0                                                                       | sentence_1                                                                        |
+  |:--------|:---------------------------------------------------------------------------------|:----------------------------------------------------------------------------------|
+  | type    | string                                                                           | string                                                                            |
+  | details | <ul><li>min: 4 tokens</li><li>mean: 12.3 tokens</li><li>max: 35 tokens</li></ul> | <ul><li>min: 8 tokens</li><li>mean: 12.08 tokens</li><li>max: 36 tokens</li></ul> |
 * Samples:
-  | sentence_0                                                                                                    | sentence_1                                                      |
-  |:--------------------------------------------------------------------------------------------------------------|:----------------------------------------------------------------|
-  | <code>Genetic diagnostic technique for SCA1-3,6,7</code>                                                      | <code>Applicant/Organization: UNIV DEGLI STUDI DI TORINO</code> |
-  | <code>Method for detecting Macrophomina phaseolina</code>                                                     | <code>Technical Classification: C12Q</code>                     |
-  | <code>System for controlled administration of a substance from a human -body-implanted infusion device</code> | <code>Applicant/Organization: Stefanini Cesare</code>           |
+  | sentence_0                                                                                                                                  | sentence_1                                                                      |
+  |:--------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------|
+  | <code>Epigenetic regulation system for the control of target gene expression</code>                                                         | <code>Applicant/Organization: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA</code> |
+  | <code>System integrating a membrane humidifier and an adsorption-based storage for polymer membrane hydrogen fuel cell applications.</code> | <code>Technical Classification: H01M</code>                                     |
+  | <code>Superconducting bipolar thermoelectric memory</code>                                                                                  | <code>Technical Classification: G11C_11</code>                                  |
 * Loss: [<code>MultipleNegativesRankingLoss</code>](https://sbert.net/docs/package_reference/sentence_transformer/losses.html#multiplenegativesrankingloss) with these parameters:
   ```json
   {
@@ -171,105 +877,107 @@ You can finetune this model on your own dataset.
 ### Training Hyperparameters
 #### Non-Default Hyperparameters
 
+- `eval_strategy`: steps
 - `per_device_train_batch_size`: 12
 - `per_device_eval_batch_size`: 12
+- `num_train_epochs`: 10
 - `multi_dataset_batch_sampler`: round_robin
 
 #### All Hyperparameters
 <details><summary>Click to expand</summary>
 
+- `do_predict`: False
+- `eval_strategy`: steps
+- `prediction_loss_only`: True
 - `per_device_train_batch_size`: 12
-- `num_train_epochs`: 3
-- `max_steps`: -1
+- `per_device_eval_batch_size`: 12
+- `gradient_accumulation_steps`: 1
+- `eval_accumulation_steps`: None
+- `torch_empty_cache_steps`: None
 - `learning_rate`: 5e-05
-- `lr_scheduler_type`: linear
-- `lr_scheduler_kwargs`: None
-- `warmup_steps`: 0
-- `optim`: adamw_torch_fused
-- `optim_args`: None
 - `weight_decay`: 0.0
 - `adam_beta1`: 0.9
 - `adam_beta2`: 0.999
 - `adam_epsilon`: 1e-08
-- `optim_target_modules`: None
-- `gradient_accumulation_steps`: 1
-- `average_tokens_across_devices`: True
 - `max_grad_norm`: 1
-- `label_smoothing_factor`: 0.0
-- `bf16`: False
-- `fp16`: False
-- `bf16_full_eval`: False
-- `fp16_full_eval`: False
-- `tf32`: None
-- `gradient_checkpointing`: False
-- `gradient_checkpointing_kwargs`: None
-- `torch_compile`: False
-- `torch_compile_backend`: None
-- `torch_compile_mode`: None
-- `use_liger_kernel`: False
-- `liger_kernel_config`: None
-- `use_cache`: False
-- `neftune_noise_alpha`: None
-- `torch_empty_cache_steps`: None
-- `auto_find_batch_size`: False
-- `log_on_each_node`: True
-- `logging_nan_inf_filter`: True
-- `include_num_input_tokens_seen`: no
+- `num_train_epochs`: 10
+- `max_steps`: -1
+- `lr_scheduler_type`: linear
+- `lr_scheduler_kwargs`: None
+- `warmup_ratio`: None
+- `warmup_steps`: 0
 - `log_level`: passive
 - `log_level_replica`: warning
-- `disable_tqdm`: False
-- `project`: huggingface
-- `trackio_space_id`: trackio
-- `eval_strategy`: no
-- `per_device_eval_batch_size`: 12
-- `prediction_loss_only`: True
-- `eval_on_start`: False
-- `eval_do_concat_batches`: True
-- `eval_use_gather_object`: False
-- `eval_accumulation_steps`: None
-- `include_for_metrics`: []
-- `batch_eval_metrics`: False
-- `save_only_model`: False
-- `save_on_each_node`: False
+- `log_on_each_node`: True
+- `logging_nan_inf_filter`: True
 - `enable_jit_checkpoint`: False
-- `push_to_hub`: False
-- `hub_private_repo`: None
-- `hub_model_id`: None
-- `hub_strategy`: every_save
-- `hub_always_push`: False
-- `hub_revision`: None
-- `load_best_model_at_end`: False
-- `ignore_data_skip`: False
+- `save_on_each_node`: False
+- `save_only_model`: False
 - `restore_callback_states_from_checkpoint`: False
-- `full_determinism`: False
+- `use_cpu`: False
 - `seed`: 42
 - `data_seed`: None
-- `use_cpu`: False
-- `accelerator_config`: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
-- `parallelism_config`: None
+- `bf16`: False
+- `fp16`: False
+- `bf16_full_eval`: False
+- `fp16_full_eval`: False
+- `tf32`: None
+- `local_rank`: -1
+- `ddp_backend`: None
+- `debug`: []
 - `dataloader_drop_last`: False
 - `dataloader_num_workers`: 0
-- `dataloader_pin_memory`: True
-- `dataloader_persistent_workers`: False
 - `dataloader_prefetch_factor`: None
+- `disable_tqdm`: False
 - `remove_unused_columns`: True
 - `label_names`: None
-- `train_sampling_strategy`: random
+- `load_best_model_at_end`: False
+- `ignore_data_skip`: False
+- `fsdp`: []
+- `fsdp_config`: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}
+- `accelerator_config`: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
+- `parallelism_config`: None
+- `deepspeed`: None
+- `label_smoothing_factor`: 0.0
+- `optim`: adamw_torch_fused
+- `optim_args`: None
+- `group_by_length`: False
 - `length_column_name`: length
+- `project`: huggingface
+- `trackio_space_id`: trackio
 - `ddp_find_unused_parameters`: None
 - `ddp_bucket_cap_mb`: None
 - `ddp_broadcast_buffers`: False
-- `ddp_backend`: None
-- `ddp_timeout`: 1800
-- `fsdp`: []
-- `fsdp_config`: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}
-- `deepspeed`: None
-- `debug`: []
+- `dataloader_pin_memory`: True
+- `dataloader_persistent_workers`: False
 - `skip_memory_metrics`: True
-- `do_predict`: False
+- `push_to_hub`: False
 - `resume_from_checkpoint`: None
-- `warmup_ratio`: None
-- `local_rank`: -1
+- `hub_model_id`: None
+- `hub_strategy`: every_save
+- `hub_private_repo`: None
+- `hub_always_push`: False
+- `hub_revision`: None
+- `gradient_checkpointing`: False
+- `gradient_checkpointing_kwargs`: None
+- `include_for_metrics`: []
+- `eval_do_concat_batches`: True
+- `auto_find_batch_size`: False
+- `full_determinism`: False
+- `ddp_timeout`: 1800
+- `torch_compile`: False
+- `torch_compile_backend`: None
+- `torch_compile_mode`: None
+- `include_num_input_tokens_seen`: no
+- `neftune_noise_alpha`: None
+- `optim_target_modules`: None
+- `batch_eval_metrics`: False
+- `eval_on_start`: False
+- `use_liger_kernel`: False
+- `liger_kernel_config`: None
+- `eval_use_gather_object`: False
+- `average_tokens_across_devices`: True
+- `use_cache`: False
 - `prompts`: None
 - `batch_sampler`: batch_sampler
 - `multi_dataset_batch_sampler`: round_robin
@@ -279,23 +987,95 @@ You can finetune this model on your own dataset.
 </details>
 
 ### Training Logs
-| Epoch  | Step | Training Loss |
-|:------:|:----:|:-------------:|
-| 1.5152 | 500  | 0.0002        |
-| 3.0303 | 1000 | 0.0000        |
-| 4.5455 | 1500 | 0.0000        |
-| 0.7622 | 500  | 2.3552        |
-| 1.5244 | 1000 | 1.9437        |
-| 2.2866 | 1500 | 1.8059        |
+| Epoch  | Step | Training Loss | mnrl-val_cosine_ndcg@10 |
+|:------:|:----:|:-------------:|:-----------------------:|
+| 1.6835 | 500  | 0.0001        | -                       |
+| 0.0954 | 50   | -             | 0.0077                  |
+| 0.1908 | 100  | -             | 0.0105                  |
+| 0.2863 | 150  | -             | 0.0147                  |
+| 0.3817 | 200  | -             | 0.0205                  |
+| 0.4771 | 250  | -             | 0.0240                  |
+| 0.5725 | 300  | -             | 0.0324                  |
+| 0.6679 | 350  | -             | 0.0348                  |
+| 0.7634 | 400  | -             | 0.0332                  |
+| 0.8588 | 450  | -             | 0.0445                  |
+| 0.9542 | 500  | 2.3022        | 0.0491                  |
+| 1.0    | 524  | -             | 0.0473                  |
+| 1.0496 | 550  | -             | 0.0479                  |
+| 1.1450 | 600  | -             | 0.0491                  |
+| 1.2405 | 650  | -             | 0.0466                  |
+| 1.3359 | 700  | -             | 0.0593                  |
+| 1.4313 | 750  | -             | 0.0547                  |
+| 1.5267 | 800  | -             | 0.0516                  |
+| 1.6221 | 850  | -             | 0.0596                  |
+| 1.7176 | 900  | -             | 0.0596                  |
+| 1.8130 | 950  | -             | 0.0681                  |
+| 1.9084 | 1000 | 1.9086        | 0.0667                  |
+| 2.0    | 1048 | -             | 0.0666                  |
+| 2.0038 | 1050 | -             | 0.0686                  |
+| 2.0992 | 1100 | -             | 0.0732                  |
+| 2.1947 | 1150 | -             | 0.0686                  |
+| 2.2901 | 1200 | -             | 0.0772                  |
+| 2.3855 | 1250 | -             | 0.0752                  |
+| 2.4809 | 1300 | -             | 0.0803                  |
+| 2.5763 | 1350 | -             | 0.0721                  |
+| 2.6718 | 1400 | -             | 0.0779                  |
+| 2.7672 | 1450 | -             | 0.0745                  |
+| 2.8626 | 1500 | 1.6854        | 0.0866                  |
+| 2.9580 | 1550 | -             | 0.0837                  |
+| 3.0    | 1572 | -             | 0.0788                  |
+| 3.0534 | 1600 | -             | 0.0752                  |
+| 3.1489 | 1650 | -             | 0.0788                  |
+| 3.2443 | 1700 | -             | 0.0845                  |
+| 3.3397 | 1750 | -             | 0.0898                  |
+| 3.4351 | 1800 | -             | 0.0920                  |
+| 3.5305 | 1850 | -             | 0.0877                  |
+| 3.6260 | 1900 | -             | 0.0926                  |
+| 3.7214 | 1950 | -             | 0.0858                  |
+| 3.8168 | 2000 | 1.5140        | 0.0889                  |
+| 3.9122 | 2050 | -             | 0.0882                  |
+| 4.0    | 2096 | -             | 0.0848                  |
+| 4.0076 | 2100 | -             | 0.0828                  |
+| 4.1031 | 2150 | -             | 0.0910                  |
+| 4.1985 | 2200 | -             | 0.0928                  |
+| 4.2939 | 2250 | -             | 0.0913                  |
+| 4.3893 | 2300 | -             | 0.0923                  |
+| 4.4847 | 2350 | -             | 0.0888                  |
+| 4.5802 | 2400 | -             | 0.0882                  |
+| 4.6756 | 2450 | -             | 0.0987                  |
+| 4.7710 | 2500 | 1.3415        | 0.0954                  |
+| 4.8664 | 2550 | -             | 0.0911                  |
+| 4.9618 | 2600 | -             | 0.0932                  |
+| 5.0    | 2620 | -             | 0.0887                  |
+| 5.0573 | 2650 | -             | 0.0952                  |
+| 5.1527 | 2700 | -             | 0.0954                  |
+| 5.2481 | 2750 | -             | 0.0972                  |
+| 5.3435 | 2800 | -             | 0.0957                  |
+| 5.4389 | 2850 | -             | 0.0999                  |
+| 5.5344 | 2900 | -             | 0.0964                  |
+| 5.6298 | 2950 | -             | 0.0980                  |
+| 5.7252 | 3000 | 1.2411        | 0.0959                  |
+| 5.8206 | 3050 | -             | 0.0943                  |
+| 5.9160 | 3100 | -             | 0.0963                  |
+| 6.0    | 3144 | -             | 0.0914                  |
+| 6.0115 | 3150 | -             | 0.0915                  |
+| 6.1069 | 3200 | -             | 0.0974                  |
+| 6.2023 | 3250 | -             | 0.1019                  |
+| 6.2977 | 3300 | -             | 0.1014                  |
+| 6.3931 | 3350 | -             | 0.1037                  |
+| 6.4885 | 3400 | -             | 0.0987                  |
+| 6.5840 | 3450 | -             | 0.1010                  |
+| 6.6794 | 3500 | 1.1304        | 0.1064                  |
+| 6.7748 | 3550 | -             | 0.1085                  |
 
 
 ### Framework Versions
-- Python: 3.12.7
+- Python: 3.12.12
 - Sentence Transformers: 5.2.3
-- Transformers: 5.3.0
-- PyTorch: 2.10.0
+- Transformers: 5.0.0
+- PyTorch: 2.10.0+cu128
 - Accelerate: 1.13.0
-- Datasets: 4.2.0
+- Datasets: 4.0.0
 - Tokenizers: 0.22.2
 
 ## Citation

config.json

@@ -19,6 +19,6 @@
   "pad_token_id": 1,
   "relative_attention_num_buckets": 32,
   "tie_word_embeddings": true,
-  "transformers_version": "5.3.0",
+  "transformers_version": "5.0.0",
   "vocab_size": 30527
 }

config_sentence_transformers.json

@@ -1,8 +1,8 @@
 {
   "__version__": {
     "sentence_transformers": "5.2.3",
-    "transformers": "5.3.0",
-    "pytorch": "2.10.0"
+    "transformers": "5.0.0",
+    "pytorch": "2.10.0+cu128"
   },
   "model_type": "SentenceTransformer",
   "prompts": {

eval/Information-Retrieval_evaluation_mnrl-val_results.csv

@@ -0,0 +1,11 @@
+epoch,steps,cosine-Accuracy@1,cosine-Accuracy@3,cosine-Accuracy@5,cosine-Accuracy@10,cosine-Precision@1,cosine-Recall@1,cosine-Precision@3,cosine-Recall@3,cosine-Precision@5,cosine-Recall@5,cosine-Precision@10,cosine-Recall@10,cosine-MRR@10,cosine-NDCG@10,cosine-MAP@100
+1.0,524,0.01653944020356234,0.03435114503816794,0.054707379134860054,0.0916030534351145,0.01653944020356234,0.01653944020356234,0.011450381679389313,0.03435114503816794,0.010941475826972013,0.054707379134860054,0.009160305343511452,0.0916030534351145,0.03400329173229936,0.04729229138376638,0.0446768559401947
+2.0,1048,0.017811704834605598,0.04580152671755725,0.06997455470737914,0.13994910941475827,0.017811704834605598,0.017811704834605598,0.015267175572519083,0.04580152671755725,0.013994910941475827,0.06997455470737914,0.013994910941475827,0.13994910941475827,0.044775637142049365,0.0666122455698021,0.05538703001323881
+3.0,1572,0.02544529262086514,0.0648854961832061,0.09033078880407125,0.15776081424936386,0.02544529262086514,0.02544529262086514,0.021628498727735368,0.0648854961832061,0.018066157760814248,0.09033078880407125,0.015776081424936386,0.15776081424936386,0.05532937517670343,0.07883996504876586,0.06667857333341984
+4.0,2096,0.021628498727735368,0.06361323155216285,0.11450381679389313,0.17302798982188294,0.021628498727735368,0.021628498727735368,0.021204410517387615,0.06361323155216285,0.022900763358778626,0.11450381679389313,0.017302798982188297,0.17302798982188294,0.05804202512217781,0.08483066508935018,0.06894986491588889
+5.0,2620,0.02544529262086514,0.07251908396946564,0.11323155216284987,0.17302798982188294,0.02544529262086514,0.02544529262086514,0.024173027989821884,0.07251908396946564,0.022646310432569976,0.11323155216284987,0.017302798982188297,0.17302798982188294,0.06303919786744216,0.08869954655146077,0.07417256951827288
+6.0,3144,0.03307888040712468,0.07633587786259542,0.11577608142493638,0.1717557251908397,0.03307888040712468,0.03307888040712468,0.025445292620865135,0.07633587786259542,0.02315521628498728,0.11577608142493638,0.01717557251908397,0.1717557251908397,0.06702512217779401,0.09136737265094202,0.07886692480908095
+7.0,3668,0.026717557251908396,0.07251908396946564,0.12086513994910941,0.19592875318066158,0.026717557251908396,0.026717557251908396,0.024173027989821884,0.07251908396946564,0.024173027989821884,0.12086513994910941,0.01959287531806616,0.19592875318066158,0.06682519487863005,0.09675471303342417,0.0768702700581889
+8.0,4192,0.030534351145038167,0.08651399491094147,0.1297709923664122,0.19592875318066158,0.030534351145038167,0.030534351145038167,0.028837998303647156,0.08651399491094147,0.025954198473282446,0.1297709923664122,0.01959287531806616,0.19592875318066158,0.07224696070115927,0.10118524847275165,0.08262985042550873
+9.0,4716,0.039440203562340966,0.09033078880407125,0.12340966921119594,0.18702290076335878,0.039440203562340966,0.039440203562340966,0.030110262934690414,0.09033078880407125,0.024681933842239184,0.12340966921119594,0.01870229007633588,0.18702290076335878,0.07651460075124207,0.10229083539418897,0.08795518859079528
+10.0,5240,0.03816793893129771,0.08651399491094147,0.1272264631043257,0.20483460559796438,0.03816793893129771,0.03816793893129771,0.028837998303647156,0.08651399491094147,0.02544529262086514,0.1272264631043257,0.02048346055979644,0.20483460559796438,0.07706288622319164,0.10668355939940834,0.08701220734782011

model.safetensors

@@ -1,3 +1,3 @@
 version https://git-lfs.github.com/spec/v1
-oid sha256:7124e7a341b5a27bb2703ada4533fd5cbeaab50189f7313fa499b4f2c132263f
+oid sha256:776b6de4d824f001cee8169d99b7e387718aa61f61203c7707f0c6cfcd599dc5
 size 437967648

tokenizer_config.json

@@ -6,18 +6,11 @@
   "eos_token": "</s>",
   "is_local": false,
   "mask_token": "<mask>",
-  "max_length": 512,
   "model_max_length": 512,
-  "pad_to_multiple_of": null,
   "pad_token": "<pad>",
-  "pad_token_type_id": 0,
-  "padding_side": "right",
   "sep_token": "</s>",
-  "stride": 0,
   "strip_accents": null,
   "tokenize_chinese_chars": true,
   "tokenizer_class": "MPNetTokenizer",
-  "truncation_side": "right",
-  "truncation_strategy": "longest_first",
   "unk_token": "[UNK]"
 }